News
08-23-2011, 03:11 AM
The toxicities associated with aromatase inhibitors (AIs) may explain the lack of overall survival improvement compared with tamoxifen, according to a study published August 22 in the Journal of The National Cancer Institute. AIs are a class of drugs used to treat breast cancer in postmenopausal women...
More... (http://www.medicalnewstoday.com/releases/233172.php)
More... (http://www.medicalnewstoday.com/releases/233172.php)